<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851408</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000480157</org_study_id>
    <secondary_id>2005-0215</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <secondary_id>NCI-2009-00131</secondary_id>
    <nct_id>NCT01851408</nct_id>
  </id_info>
  <brief_title>Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma</brief_title>
  <official_title>Phase 2 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II portion of the trial is studying the side effects and best dose of temsirolimus&#xD;
      when given together with sorafenib and to see how well they work in treating patients with&#xD;
      metastatic, recurrent, or unresectable melanoma. Sorafenib and temsirolimus may stop the&#xD;
      growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may&#xD;
      also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib&#xD;
      together with temsirolimus may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the clinical activity, in terms of overall response rate (complete and&#xD;
           partial response), of this regimen in these patients. (Phase II)&#xD;
&#xD;
        -  To evaluate the in vivo biological activity of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the progression-free survival and overall survival of patients treated with&#xD;
      this regimen.&#xD;
&#xD;
      II. To determine the safety and toxicity of this regimen in these patients.&#xD;
&#xD;
      III. To Determine the population pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      IV. To correlate tumor and blood biomarkers with clinical outcome in patients treated with&#xD;
      this regimen.&#xD;
&#xD;
      OUTLINE: Upon completion of the multicenter, phase I, dose-escalation study followed to be&#xD;
      followed by this phase II, open-label study.&#xD;
&#xD;
      Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and oral sorafenib&#xD;
      once or twice daily on days 1-28. Treatment course repeats every 28 days for up to 6 courses&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3-6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No progression of Phase 1 trial to Phase 2.&#xD;
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (complete response and partial response) CCI-779 in combination with BAY43-9006</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>The duration of time from start of treatment to date of first evidence of progression or the date of last follow-up for patients who do not progress, assessed up to 5 years</time_frame>
    <description>Kaplan-Meier life table methods and Cox proportional hazards regression modeling will be utilized to analyze progression-free survival and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Kaplan-Meier life table methods and Cox proportional hazards regression modeling will be utilized to analyze progression-free survival and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noncompartmental pharmacokinetic parameters of BAY43-9006 and CCI-779 estimated using a validated commercial software</measure>
    <time_frame>Week 1 and 3</time_frame>
    <description>Maximum concentration (Cmax) and time to Cmax (tmax) will be the observed values. Area under the plasma concentration-time curve from zero to last observable time (AUClast).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage III Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Temsirolimus + Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Temsirolimus + Sorafenib</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Temsirolimus + Sorafenib</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>cell cycle inhibitor 779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed melanoma, meeting 1 of the following&#xD;
             criteria: recurrent or unresectable stage III disease, stage IV disease, non-choroidal&#xD;
             origin.&#xD;
&#xD;
          -  Tumor must be accessible to biopsy unless appropriate tumor sample collection has&#xD;
             occurred within the past 3 months and patient agrees to provide these samples for this&#xD;
             study.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine normal or creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after&#xD;
             completion of study treatment.&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to sorafenib or temsirolimus.&#xD;
&#xD;
          -  No uncontrolled hypertension, defined as systolic blood pressure &gt; 140 mm Hg on 2&#xD;
             separate days &lt; 1 week prior to study entry OR diastolic pressure &gt; 90 mm Hg on 2&#xD;
             separate days &lt; 1 week prior to study entry.&#xD;
&#xD;
          -  No evidence of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  No condition that would impair the ability to swallow pills (e.g., gastrointestinal&#xD;
             tract disease resulting in an inability to take oral medication; requirement for IV&#xD;
             alimentation; or active peptic ulcer disease).&#xD;
&#xD;
          -  No uncontrolled illness including, but not limited to, any of the following: ongoing&#xD;
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia or psychiatric illness or social situations that would limit study&#xD;
             compliance.&#xD;
&#xD;
          -  No traumatic injury within the past 3 weeks.&#xD;
&#xD;
          -  No more than 1 prior systemic chemotherapy regimen for metastatic melanoma (Phase II).&#xD;
&#xD;
          -  No prior sorafenib, temsirolimus, or any other agents targeting raf, vascular&#xD;
             endothelial growth factor (VEGF)/VEGF receptor, or mTOR (Phase II).&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption.&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery.&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)&#xD;
             for melanoma and recovered.&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered.&#xD;
&#xD;
          -  Prior biologic or immunotherapeutic regimens allowed.&#xD;
&#xD;
          -  Prior regional chemotherapy regimens (e.g., isolated limb perfusion) allowed but only&#xD;
             1 prior regional chemotherapy regimen allowed if all target lesions are within the&#xD;
             prior regional treatment field.&#xD;
&#xD;
          -  No concurrent enzyme-inducing antiepileptic drugs including, but not limited to, any&#xD;
             of the following: phenytoin, carbamazepine, phenobarbital, rifampin or Hypericum&#xD;
             perforatum (St. John's wort).&#xD;
&#xD;
          -  No concurrent prophylactic hematopoietic colony-stimulating factors.&#xD;
&#xD;
          -  No other concurrent investigational agents.&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies for this cancer.&#xD;
&#xD;
          -  No concurrent full-dose anticoagulation (i.e., warfarin, IV heparin, or low-molecular&#xD;
             weight heparin).&#xD;
&#xD;
          -  No concurrent grapefruit or grapefruit juice.&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients.&#xD;
&#xD;
          -  Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin) allowed&#xD;
             provided prothrombin time (PT) international normalized ratio (INR) &lt; 1.1 times upper&#xD;
             limits of normal (ULN).&#xD;
&#xD;
          -  Unidimensionally measurable disease &gt;= 20 mm by conventional techniques or &gt;= 10 mm by&#xD;
             spiral computed tomography (CT) scan (longest diameter to be recorded) and margins of&#xD;
             visible cutaneous metastatic lesions should be clearly defined and measured in at&#xD;
             least one dimension as &gt;= 10 mm.&#xD;
&#xD;
          -  No known brain metastases unless the following criteria are met: no radiographical&#xD;
             evidence of recurrences in the brain &gt;= 3 months after complete resection of the brain&#xD;
             metastases, asymptomatic brain metastases stable for &gt;= 3 months since whole-brain&#xD;
             radiation therapy and/or stereotactic radiosurgery and must not require steroid for&#xD;
             brain metastases.&#xD;
&#xD;
          -  White Blood Count (WBC) &gt;= 3,000/mm³&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm³&#xD;
&#xD;
          -  Serum cholesterol =&lt; 350 mg/dL&#xD;
&#xD;
          -  Triglycerides =&lt; 400 mg/dL&#xD;
&#xD;
          -  Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =&lt; 2.5 times upper&#xD;
             limit of normal.&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 2.&#xD;
&#xD;
          -  At least 5 years since prior chemotherapy for other types of cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center official website</description>
  </link>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>Temsirolimus</keyword>
  <keyword>Stage IV</keyword>
  <keyword>recurrent</keyword>
  <keyword>unresectable</keyword>
  <keyword>non-choroidal origin</keyword>
  <keyword>CCI-779</keyword>
  <keyword>BAY43-9006</keyword>
  <keyword>metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

